V. Rustgi

p53 mutation in hepatocellular carcinoma after aflatoxin exposure

Brigitte Bressac–de Paillerets, Alain Puisieux, Michael C. Kew et al. · The Lancet · 1991 · 449 citations

Hepatology, Liver Physiology, P53 Mutation +5

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

Anna S. Lok, David Gardiner, Eric Lawitz et al. · Journal of Hepatology · 2011 · 65 citations · Full text

Viral Hepatitis, Immunology, Antiviral Therapy +5

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2011 · 46 citations

Viral Persistence, Viral Hepatitis, Immunodeficiencies +10

Omeprazole is superior to ranitidine plus metoclopramide in the short‐term treatment of erosive oesophagitis

Malcolm Robinson, Dennis L. Decktor, Paul N. Maton et al. · Alimentary Pharmacology & Therapeutics · 1993 · 37 citations

1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS

Gregory T. Everson, Karen Sims, M. Rodríguez‐Torres et al. · Journal of Hepatology · 2013 · 37 citations · Full text

Hepatology, Hepatitis C, Regimen Of Daclatasvir +11